BioDrugs

, Volume 15, Issue 5, pp 325–337 | Cite as

Immunological Aspects of Alzheimer’s Disease

Therapeutic Implications
  • Jeroen J. M. Hoozemans
  • Annemieke J.M. Rozemuller
  • Robert Veerhuis
  • Piet Eikelenboom
Review Article

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disease causing progressive impairment of memory and cognitive function. The amyloid cascade hypothesis suggests that mismetabolism of the β-amyloid (Aβ) precursor protein (APP) followed by subsequent formation of non-fibrillar and fibrillar Aβ deposits leads to glial activation and eventually to neurotoxicity, causing cognitive impairment. Several lines of evidence indicate that an inflammatory process contributes to the pathology of AD. First, inflammatory proteins have been identified as being associated with neuritic plaques and in glial cells surrounding these plaques. Second, certain polymorphisms of acute-phase proteins and cytokines associated with AD plaques increase the risk or predispose for earlier onset of developing AD. Third, epidemiological studies indicate that anti-inflammatory drugs can retard the development of AD. Several steps in the pathological cascade of AD have been identified as possible targets for actions of nonsteroidal anti-inflammatory drugs. For instance, microglia are considered a target because this cell type is closely involved in AD pathology through secretion of neurotoxic substances and by modulating a positive feedback loop of the inflammatory mechanism that may be involved in the pathological cascade in AD. On the basis of studies in APP transgenic mice, immunisation with Aβ was recently suggested as a novel immunological approach for the treatment of AD. Immunisation elicits Aβ-specific antibodies that could affect several early steps of the amyloid-driven cascade. Antibodies could prevent Aβ from aggregating into fibrils and accelerate clearance of Aβ by stimulating its removal by microglial cells. This review outlines the pathological and genetic evidence that an inflammatory mechanism is involved in AD and the therapeutic approaches based on inhibition or mediation of inflammation.

Notes

Acknowledgements

Recent work discussed in this review was supported financially by the European Community (QLK6-CT-1999-02004) and by the Internationale Stichting Alzheimer Onderzoek (ISAO grant no. 97508).

References

  1. 1.
    Selkoe DJ. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer’s disease. Curr Opin Neurobiol 1994; 4(5): 708–16PubMedGoogle Scholar
  2. 2.
    Dickson DW. Neuropathological diagnosis of Alzheimer’s disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 1997; 18Suppl. 4: S21–6PubMedGoogle Scholar
  3. 3.
    Rozemuller JM, Eikelenboom P, Stam FC, et al. A4 protein in Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 1989; 48(6): 674–91PubMedGoogle Scholar
  4. 4.
    Ogomori K, Kitamoto T, Tateishi J, et al. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer’s disease. Am JPathol 1989; 134(2): 243–51Google Scholar
  5. 5.
    Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 1989; 135(2): 309–19PubMedGoogle Scholar
  6. 6.
    Mann DM. Cerebral amyloidosis, ageing and Alzheimer’s disease; a contribution from studies on Down’s syndrome. Neurobiol Aging 1989; 10(5): 397–9PubMedGoogle Scholar
  7. 7.
    Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21(3): 383–421PubMedGoogle Scholar
  8. 8.
    Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol Berl 1982; 57(2-3): 239–42PubMedGoogle Scholar
  9. 9.
    Rozemuller JM, Eikelenboom P, Pals ST, et al. Microglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 1989; 101(3): 288–92PubMedGoogle Scholar
  10. 10.
    Eikelenboom P, Zhan SS, van Gool WA, et al. Inflammatory mechanisms in Alzheimer’s disease. Trends Pharmacol Sci 1994; 15(12): 447–50PubMedGoogle Scholar
  11. 11.
    McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996; 47(2): 425–32PubMedGoogle Scholar
  12. 12.
    McGeer PL, Akiyama H, Itagaki S, et al. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989; 107(1-3): 341–6PubMedGoogle Scholar
  13. 13.
    Rogers J, Cooper NR, Webster S, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89(21): 10016–20PubMedGoogle Scholar
  14. 14.
    Webster S, Bradt B, Rogers J, et al. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem 1997; 69(1): 388–98PubMedGoogle Scholar
  15. 15.
    Veerhuis R, Janssen I, Hoozemans JJ, et al. Complement C1-inhibitor expression in Alzheimer’s disease. Acta Neuropathol Berl 1998; 96(3): 287–96PubMedGoogle Scholar
  16. 16.
    Griffin WS, Sheng JG, Roberts GW, et al. Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54(2): 276–81PubMedGoogle Scholar
  17. 17.
    Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 1991; 285(1): 111–4PubMedGoogle Scholar
  18. 18.
    Fillit H, Ding WH, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett 1991; 129(2): 318–20PubMedGoogle Scholar
  19. 19.
    Blum-Degen D, Muller T, Kuhn W, et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alz-heimer’s and de novo Parkinson’s disease patients. Neurosci Lett 1995; 202(1-2): 17–20PubMedGoogle Scholar
  20. 20.
    Cacabelos R, Barquero M, Garcia P, et al. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer’s disease and neu-rological disorders. Methods Find Exp Clin Pharmacol 1991; 13(7): 455–8PubMedGoogle Scholar
  21. 21.
    Tarkowski E, Blennow K, Wallin A, et al. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999; 19(4): 223–30PubMedGoogle Scholar
  22. 22.
    Rothwell N, Allan S, Toulmond S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest 1997; 100(11): 2648–52PubMedGoogle Scholar
  23. 23.
    Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-betal in transgenic mice and in Alzheimer’s disease. Nature 1997; 389(6651): 603–6PubMedGoogle Scholar
  24. 24.
    Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia 1993; 7(1): 75–83PubMedGoogle Scholar
  25. 25.
    Abraham CR. The role of the acute-phase protein alpha 1-antichymotrypsin in brain dysfunction and injury. Res Immunol 1992; 143(6): 631–6PubMedGoogle Scholar
  26. 26.
    Namba Y, Ikeda K. Apolipoprotein B immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in senile dementia of Alzheimer type. Rinsho Shinkeigaku 1991; 31(8): 826–30PubMedGoogle Scholar
  27. 27.
    McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7(1): 84–92PubMedGoogle Scholar
  28. 28.
    Snow AD, Sekiguchi R, Nochlin D, et al. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994; 12(1): 219–34PubMedGoogle Scholar
  29. 29.
    Norling B, Westermark GT, Westermark P. Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis. Clin Exp Immunol 1988; 73(2): 333–7PubMedGoogle Scholar
  30. 30.
    Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989; 86(19): 7606–10PubMedGoogle Scholar
  31. 31.
    Blasko I, Marx F, Steiner E, et al. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13(1): 63–8PubMedGoogle Scholar
  32. 32.
    Zhan SS, Veerhuis R, Kamphorst W, et al. Distribution of beta amyloid associated proteins in plaques in Alzheimer’s disease and in the non-demented elderly. Neurodegeneration 1995; 4(3): 291–7PubMedGoogle Scholar
  33. 33.
    Webster SD, Yang AJ, Margol L, et al. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol 2000; 161(1): 127–38PubMedGoogle Scholar
  34. 34.
    Nakamura Y, Si QS, Kataoka K. Lipopolysaccharide-induced microglial activation in culture: temporal profiles of morphological change and release of cytokines and nitric oxide. Neurosci Res 1999; 35(2): 95–100PubMedGoogle Scholar
  35. 35.
    Veerhuis R, Janssen I, De Groot CJ, et al. Cytokines associated with amyloid plaques in Alzheimer’s disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins,but not C1-inhibitor. Exp Neurol 1999; 160(1): 289–99PubMedGoogle Scholar
  36. 36.
    Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer beta amyloid peptide. BiochemBiophys Res Commun 1994; 199(2): 984–91Google Scholar
  37. 37.
    Rozemuller JM, Bots GT, Roos RA, et al. Acute phase proteins but not activated microglial cells are present in parenchymal beta/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurosci Lett 1992; 140(2): 137–40PubMedGoogle Scholar
  38. 38.
    Maat-Schieman ML, Rozemuller AJ, van Duinen SG, et al. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis (Dutch). An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53(5): 483–91PubMedGoogle Scholar
  39. 39.
    Eikelenboom P, Rozemuller JM, Van Muiswinkel FL. Inflammation and Alzheimer’s disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 1998; 154(1): 89–98PubMedGoogle Scholar
  40. 40.
    Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer’s disease. Neurosci Lett 1990; 119(1): 75–8PubMedGoogle Scholar
  41. 41.
    Yasojima K, Schwab C, McGeer EG, et al. Up-regulated production and activation of the complement system in Alz-heimer’s disease brain. Am J Pathol 1999; 154(3): 927–36PubMedGoogle Scholar
  42. 42.
    Verbeek MM, Otte-Holler I, Westphal JR, et al. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer’s disease. Am J Pathol 1994; 144(1): 104–16PubMedGoogle Scholar
  43. 43.
    Gibson GE, Blass JP, Huang HM, et al. The cellular basis of delirium and its relevance to age-related disorders including Alzheimer’s disease. Int Psychogeriatr 1991; 3(2): 373–95PubMedGoogle Scholar
  44. 44.
    Lipowski ZJ. Delerium: acute confusional state. Oxford: Oxford University Press, 2001Google Scholar
  45. 45.
    McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Mov Disord 1997; 12(6): 855–8PubMedGoogle Scholar
  46. 46.
    Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience 1999; 88(1): 193–200PubMedGoogle Scholar
  47. 47.
    Willard LB, Hauss-Wegrzyniak B, Danysz W, et al. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 2000; 134(1): 58–65PubMedGoogle Scholar
  48. 48.
    Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391(6664): 281–5PubMedGoogle Scholar
  49. 49.
    Arends YM, Duyckaerts C, Rozemuller JM, et al. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 2000; 21(1): 39–47PubMedGoogle Scholar
  50. 50.
    Yermakova AV, Rollins J, Callahan LM, et al. Cyclooxygenase1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58(11): 1135–46PubMedGoogle Scholar
  51. 51.
    Ho L, Pieroni C, Winger D, et al. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease. J Neurosci Res 1999; 57(3): 295–303PubMedGoogle Scholar
  52. 52.
    Yasojima K, Schwab C, McGeer EG, et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999; 830(2): 226–36PubMedGoogle Scholar
  53. 53.
    Hoozemans JJ, Rozemuller AJ, Janssen I, et al. Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain. Acta Neuropathol Berl 2001; 101(1): 2–8PubMedGoogle Scholar
  54. 54.
    Bagli M, Papassotiropoulos A, Knapp M, et al. Association between an interleukin-6 promoter and 3 flanking region haplotype and reduced Alzheimer’s disease risk in a German population. Neurosci Lett 2000; 283(2): 109–12PubMedGoogle Scholar
  55. 55.
    Bhojak TJ, DeKosky ST, Ganguli M, et al. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer’s disease. Neurosci Lett 2000; 288(1): 21–4PubMedGoogle Scholar
  56. 56.
    Du Y, Dodel RC, Eastwood BJ, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer’s disease. Neurology 2000; 55(4): 480–3PubMedGoogle Scholar
  57. 57.
    Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 2000; 47(3): 365–8PubMedGoogle Scholar
  58. 58.
    Grimaldi LM, Casadei VM, Ferri C, et al. Association of early-onset Alzheimer’s disease with an interleukin-1 alpha gene polymorphism. Ann Neurol 2000; 47(3): 361–5PubMedGoogle Scholar
  59. 59.
    Licastro F, Pedrini S, Ferri C, et al. Gene polymorphism affecting alphal-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer’s disease risk. Ann Neurol 2000; 48(3): 388–91PubMedGoogle Scholar
  60. 60.
    Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19(4): 357–60PubMedGoogle Scholar
  61. 61.
    Blennow K, Ricksten A, Prince JA, et al. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000; 107(8-9): 1065–79PubMedGoogle Scholar
  62. 62.
    Koster MN, Dermaut B, Cruts M, et al. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000; 55(5): 678–84PubMedGoogle Scholar
  63. 63.
    Halimi G, Duplan L, Bideau C, et al. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer’s disease. Neuroreport 2000; 11(16): 3599–601PubMedGoogle Scholar
  64. 64.
    McCusker SM, Curran MD, Dynan KB, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimers disease and vascular dementia: a case control study. Lancet 2001; 357: 436–9PubMedGoogle Scholar
  65. 65.
    Lanzrein AS, Johnston CM, Perry VH, et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1 beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alphal-antichymotrypsin. Alzheimer Dis Assoc Disord 1998; 12(3): 215–27PubMedGoogle Scholar
  66. 66.
    Engelborghs S, de Brabander M, de Cree J, et al. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int 1999; 34(6): 523–30PubMedGoogle Scholar
  67. 67.
    Marz P, Heese K, Hock C, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett 1997; 239(1): 29–32PubMedGoogle Scholar
  68. 68.
    Jenkinson ML, Bliss MR, Brain AT, et al. Rheumatoid arthritis and senile dementia of the Alzheimer’s type [letter]. Br J Rheumatol 1989; 28(1): 86–8PubMedGoogle Scholar
  69. 69.
    McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease [letter]. Lancet 1990; 335(8696): 1037PubMedGoogle Scholar
  70. 70.
    Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44(2): 227–32PubMedGoogle Scholar
  71. 71.
    Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995; 45(8): 1441–5PubMedGoogle Scholar
  72. 72.
    Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer’s disease: a current appraisal. Neurobiol Aging 1996; 17(5): 789–94PubMedGoogle Scholar
  73. 73.
    Lucca U. Nonsteroidal anti-inflammatory drugs and Alzheimers: update on recent data and their therapeutical implications. CNS Drugs 1999; 11: 207–24Google Scholar
  74. 74.
    in t Veld BA, Launer LJ, Hoes AW, et al. NS AIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging 1998; 19(6): 607–11Google Scholar
  75. 75.
    in t Veld BA, Ruitenberg A, Launer LJ, et al. NSAID and the risk of Alzheimers disease and vascular dementia. The Rotterdam study. In: Thesis by in t Veld BA. Pharmacological prevention of dementia. Rotterdam, The Netherlands: Erasmus University Medical School, 2000Google Scholar
  76. 76.
    Fiebich BL, Mueksch B, Boehringer M, et al. Interleukin-1 beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. J Neurochem 2000; 75(5): 2020–8PubMedGoogle Scholar
  77. 77.
    Hoozemans JJ, Veerhuis R, Janssen I, et al. Interleukin-1 beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: Implications for Alzheimer’s disease. Exp Gerontol 2001; 36(3): 559–70PubMedGoogle Scholar
  78. 78.
    Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000; 20(15): 5709–14PubMedGoogle Scholar
  79. 79.
    Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272(6): 3406–10PubMedGoogle Scholar
  80. 80.
    Kitamura Y, Shimohama S, Koike H, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains. Biochem Biophys Res Commun 1999; 254(3): 582–6PubMedGoogle Scholar
  81. 81.
    Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prosta-glandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Deltal2,14-prostaglandin J2. Proc Natl Acad Sci USA 1999; 96(8): 4668–73PubMedGoogle Scholar
  82. 82.
    Bernardo A, Levi G, Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Deltal2, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000; 12(7): 2215–23PubMedGoogle Scholar
  83. 83.
    Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391(6662): 79–82PubMedGoogle Scholar
  84. 84.
    Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391(6662): 82–6PubMedGoogle Scholar
  85. 85.
    Combs CK, Johnson DE, Karlo JC, et al. Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20(2): 558–67PubMedGoogle Scholar
  86. 86.
    Stephenson D, Rash K, Smalstig B, et al. Cytosolic phos-pholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 1999; 27(2): 110–28PubMedGoogle Scholar
  87. 87.
    Stephenson DT, Lemere CA, Selkoe DJ, et al. Cytosolic phos-pholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain. Neurobiol Dis 1996; 3(1): 51–63PubMedGoogle Scholar
  88. 88.
    Stella N, Estelles A, Siciliano J, et al. Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. J Neurosci 1997; 17(9): 2939–46PubMedGoogle Scholar
  89. 89.
    Blom MA, vanTwillert MG, de Vries SC, et al. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res 1997; 777(1-2): 210–8PubMedGoogle Scholar
  90. 90.
    Fiebich BL, Hull M, Lieb K, et al. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem 1997; 68(2): 704–9PubMedGoogle Scholar
  91. 91.
    Lee RK, Knapp S, Wurtman RJ. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J Neurosci 1999; 19(3): 940–7PubMedGoogle Scholar
  92. 92.
    Licastro F, Davis LJ, Pedrini S, et al. Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: implications for Alzheimer’s disease. Biochem Biophys Res Commun 1998; 249(1): 182–6PubMedGoogle Scholar
  93. 93.
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 Jul 8; 400(6740): 173–7PubMedGoogle Scholar
  94. 94.
    Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 2000; 48(4): 567–79PubMedGoogle Scholar
  95. 95.
    Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993; 52(6): 594–600PubMedGoogle Scholar
  96. 96.
    Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 1992; 140(6): 1389–99PubMedGoogle Scholar
  97. 97.
    Li R, Shen Y, Yang LB, et al. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 2000; 75(4): 1447–54PubMedGoogle Scholar
  98. 98.
    Frenkel D, Balass M, Katchalski-Katzir E, et al. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J Neuroimmunol 1999; 95(1-2): 136–42PubMedGoogle Scholar
  99. 99.
    Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6(8): 916–9PubMedGoogle Scholar
  100. 100.
    St George-Hyslop PH, Westaway DA. Antibody clears senile plaques. Nature 2000; 400: 116–7Google Scholar
  101. 101.
    Chen G, Chen KS, Knox J, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Nature 2000; 408(6815): 975–9PubMedGoogle Scholar
  102. 102.
    Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 2000; 408(6815): 979–82PubMedGoogle Scholar
  103. 103.
    Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000; 408(6815): 982–5PubMedGoogle Scholar
  104. 104.
    Spiegel K, Emmerling MR, Barnum SR. Strategies for inhibition of complement activation in the treatment of neurod-egenerative diseases. In: Wood PL, editor. Neuroinflammation: mechanisms and management. Towota: Humana Press Inc., 1997: 129-76Google Scholar
  105. 105.
    Webster SD, Bonnell BS, Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am J Pathol 1997; 150(5): 1531–6PubMedGoogle Scholar
  106. 106.
    Huang J, Kim LJ, Mealey R, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285: 595–9PubMedGoogle Scholar
  107. 107.
    Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54(3): 588–93PubMedGoogle Scholar
  108. 108.
    Rother M, Erkinjutti T, Roessner M, et al. Propentofylline in the treatment of Alzheimers disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord 1998; 9(1): 36–43PubMedGoogle Scholar
  109. 109.
    Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43(8): 1609–11PubMedGoogle Scholar
  110. 110.
    Sainali SM, Ingram DM, Talwker S, et al. Results of a doubleblind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer’s disease [abstract]. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy; 2000 Apr 5–8: StockholmGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Jeroen J. M. Hoozemans
    • 1
    • 2
  • Annemieke J.M. Rozemuller
    • 3
  • Robert Veerhuis
    • 1
    • 2
  • Piet Eikelenboom
    • 1
  1. 1.Department of Psychiatry, Graduate School of Neurosciences AmsterdamResearch Institute Neurosciences Vrije Universiteit, Vrije Universiteit Medical CenterAmsterdamThe Netherlands
  2. 2.Department of Pathology, Graduate School of Neurosciences AmsterdamResearch Institute Neurosciences Vrije Universiteit, Vrije Universiteit Medical CenterAmsterdamThe Netherlands
  3. 3.Department of PathologyAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations